# US 4,397,392 A · Contained blood gas control > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 4,397,392 A - Document ID: US4397392A - Status: Granted - Kind: A - Application number: 06/223,364 - Filed: 1981-01-08 - Granted: 1983-08-09 - Earliest claimed: 1981-01-08 - Assignees: Intensive Technology, Inc. - Inventors: Alan H. Runck; G. Joseph Beatrice - Web page: https://patentgrep.com/patent/US4397392A ## CPC - G01N 33/96: involving blood or serum control standard - G01N 2496/70: Blood gas control solutios containing dissolved oxygen, bicarbonate and the like - Y10T 436/102499: Blood gas standard or control - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION ## Abstract A chemical seal for isolating the liquid phase of a contained liquid from the vapor phase present in the container headspace comprises a chemically impregnated gel formed by mixing a biopolymer gel, a high molecular weight polymer and chemical impregnants with water to form a gel-forming aqueous solution which is applied to the surface of the contained liquid and allowed to solidify thereby forming a mechanically stable, chemically impregnated gel seal in intimate contact with the contained liquid. ## Claims ### Claim 1 A process for isolating a contained blood gas control from the remaining headspace in the container comprising partially filling a container with a blood gas control, applying an aqueous polymer gel-forming solution to the surface of the blood gas control thereby partially filling the headspace in the container and allowing the solution to form a mechanically stable, thin but nonporous, plural phase gel seal in intimate contact with the surface of the contained blood that prevents changes in equilibration between the liquid and gaseous phases of the control. ### Claim 2 (depends on 1) The process defined in claim 1 wherein the applying step is performed by injecting the solution onto an interior wall of the container just above the surface of the blood gas control so that the solution is carefully layered onto the surface of the blood gas control. ### Claim 3 (depends on 1) The process defined in claim 1 wherein the solution is maintained at an elevated temperature in excess of about 30.degree. C. prior to its introduction into the container. ### Claim 4 (depends on 3) The process defined in claim 3 wherein said temperature is in the order of 60.degree. C. ### Claim 5 (depends on 3) The process defined in claim 3 wherein the allowing step includes subjecting the container and its contents to a reduced temperature of between about 0.degree. C. to 10.degree. C. ### Claim 6 (depends on 5) The process defined in claim 5 wherein said reduced temperature is about 4.degree. C. ### Claim 7 (depends on 1) The method defined in claim 1 and including the additional step of adding one or more chemicals to the solution to form an impregnant in the gel seal in intimate contact with the contained blood gas control. ### Claim 8 A process for preparing a chemical seal for isolating the gaseous and liquid phases of a contained blood gas control comprising the steps of forming an aqueous solution of a water soluble gel, a water soluble high molecular weight polymer, the gel and polymer each being present in an amount of from 0.5 to 6 percent (weight per volume of solution); subjecting the solution to an elevated temperature sufficient to maintain it in a liquid phase until use; carefully applying the solution onto the surface of the contained blood gas control to be sealed until that surface is completely covered; and allowing the contained blood gas control and solution to cool sufficiently to cause the solution to form a mechanically stable, thin but nonporous, plural phase gel seal in intimate contact with the blood gas control thereby forming a barrier between the blood gas control and the remaining headspace in the container that prevents changes in equilibration between the liquid and gaseous phases of the control. ### Claim 9 (depends on 8) The process defined in claim 8 wherein the solution is maintained at a temperature of about 60.degree. C. until use and cooled to a temperature of about 4.degree. C. after it is applied to the blood gas control. ### Claim 10 (depends on 8) The process defined in claim 8 wherein a biopolymer gel selected from the group consisting of agarose and collagen and a polymer selected from the group consisting of polyvinylpyrrolidone, hydroxyethyl starch and dextran are mixed together to form said aqueous solution. ### Claim 11 (depends on 10) The process defined in claim 10 wherein the gel and polymer are each present in the amount of about one percent (weight per volume of solution). ### Claim 12 (depends on 8) The process defined in claim 8 and further including the additional step of adding to said solution one or more water soluble chemicals which impregnate the resultant gel seal so as to preserve the effectiveness of the contained blood gas control. ### Claim 13 (depends on 12) The process defined in claim 12 wherein said added chemicals include an antibiotic. ### Claim 14 (depends on 12) The process defined in claim 12 wherein the added chemicals include sodium chloride. ### Claim 15 A contained blood gas control comprising a container, a volume of blood gas control partially filling the container and a chemical seal for said control formed by mixing a water soluble biopolymer gel, a water soluble high molecular weight polymer and one or more selected water soluble blood compatible chemicals in water at an elevated temperature to form an aqueous solution, the gel and polymer each being present in an amount of from 0.5 to 6 percent (weight per volume of solution), layering the solution on the surface of the contained control and allowing the solution to cool until it forms a mechanically stable, thin but nonporous, plural phase gel seal at the surface of the control which is impregnated with said chemicals, is compatible with blood, is nonporous to the blood gases in the control and prevents changes in equilibrium between the liquid and gaseous phases in the blood gas control in the container. ### Claim 16 (depends on 15) The seal defined in claim 15 wherein the biopolymer gel is selected from the group consisting of agarose and collagen. ### Claim 17 (depends on 15) The seal defined in claim 15 wherein the polymer is selected from the group consisting of polyvinylpyrrolidone, hydroxyethyl starch and dextran. ### Claim 18 (depends on 15) The seal defined in claim 15 wherein the chemicals include an antibiotic. ### Claim 19 (depends on 15) The seal defined in claim 15 wherein the chemicals include sodium chloride.